Impact of Gender on the Outcome of Liver Transplantation for Hepatocellular Carcinoma

NCT05643833 | Completed

• 1 other identifier: CT2022-ZJU-OBS1
• Study Type: observational
• Target: 3,769
• Locations: 1 country
• Sites: 1

Brief Summary

This is a large-scale study in China to provide evidence and insights in the role of gender in LT for HCC by analyzing the data of 3769 recipients with HCC registered in the China Liver Transplant Registry.

Conditions

Cancer of Liver

Outcome Measures

Primary Outcomes (1)

• Overall survival

  the overall survival of liver transplant recipient with HCC

  January 2015 to December 2020

Study Arms (4)

Male recipient

Other: no intervention

Female recipient

Other: no intervention

Male donor

Other: no intervention

Female donor

Other: no intervention

Interventions

no intervention OTHER

no intervention

Female donor; Female recipient; Male donor; Male recipient

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

A total of 3769 HCC patients underwent liver transplant with the age between 18-65 years old were studied.

You may qualify if:

• The patients with liver transplants performed from January 2015 to December 2020, whose clinicopathological data were registered in the CLTR.

You may not qualify if:

• Patients with following features were excluded: with concurrent other malignancies, pathologically-confirmed tumor types other than HCC, such as intrahepatic cholangiocarcinoma (ICC), combined hepatocellular cholangiocarcinoma (cHCC-CC), fibrolamellar hepatocellular carcinoma (FLC) or secondary metastatic tumor; without histological confirmation of HCC for transplantation. The patients who received living donor liver transplantation, split liver transplantation, reduced-size liver transplantation or simultaneous transplantation were also excluded. Next, pediatric patients (\<18 years) or senile patients (\>65 years) and those patients who died within six months after transplantation were also excluded. Finally, the patients with type-1 and type-2 portal vein tumor thrombus (PVTT), tumor metastasis, having doubtful or contradictory data or missing essential data for analysis, re-transplantation during follow-up time were excluded as well.

Sponsors & Collaborators

• Zhejiang University: lead

Study Sites (1)

Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310003, China

Location

MeSH Terms

Conditions

Liver Neoplasms

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Liver Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: November 29, 2022
• First Posted: December 9, 2022
• Study Start: January 1, 2021
• Primary Completion: May 30, 2022
• Study Completion: October 15, 2022
• Last Updated: December 9, 2022

Record last verified: 2022-11

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)